CorMedix Inc Operating Expenses 2011-2025 | CRMD

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

CorMedix Inc operating expenses from 2011 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

CorMedix Inc operating expenses from 2011 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$222.7B
Amgen (AMGN)	$161.5B
Gilead Sciences (GILD)	$142.5B
Vertex Pharmaceuticals (VRTX)	$123.1B
Bristol Myers Squibb (BMY)	$98.7B
GSK (GSK)	$81B
CSL (CSLLY)	$78.2B
Regeneron Pharmaceuticals (REGN)	$60.4B
Alnylam Pharmaceuticals (ALNY)	$42.1B
Argenex SE (ARGX)	$34.4B
BioNTech SE (BNTX)	$27.4B
Royalty Pharma (RPRX)	$20.3B
Biogen (BIIB)	$19.8B
Insmed (INSM)	$18.3B
Illumina (ILMN)	$15.8B
Genmab (GNMSF)	$14B
Genmab (GMAB)	$14B
Incyte (INCY)	$13.6B
Moderna (MRNA)	$13.3B
Exelixis (EXEL)	$12.3B
BioMarin Pharmaceutical (BMRN)	$11.3B
QIAGEN (QGEN)	$10.8B
Ascendis Pharma (ASND)	$10.8B
Swedish Orphan Biovitrum (BIOVF)	$10.4B
Exact Sciences (EXAS)	$10.1B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Bio-Techne Corp (TECH)	$8.5B
Blueprint Medicines (BPMC)	$8.4B
Regencell Bioscience Holdings (RGC)	$8.2B
Roivant Sciences (ROIV)	$7.9B